We are analyzing https://link.springer.com/article/10.1007/s11095-014-1609-7.

Title:
Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) | Pharmaceutical Research
Description:
Purpose Regorafenib is a novel multikinase inhibitor, currently approved for the treatment of metastasized colorectal cancer and advanced gastrointestinal stromal tumors. We investigated whether regorafenib is a substrate for the multidrug efflux transporters ABCG2 and ABCB1 and whether oral availability, brain and testis accumulation of regorafenib and its active metabolites are influenced by these transporters. Methods We used in vitro transport assays to assess human (h)ABCB1- or hABCG2- or murine (m)Abcg2-mediated active transport at high and low concentrations of regorafenib. To study the single and combined roles of Abcg2 and Abcb1a/1b in oral regorafenib disposition and the impact of Cyp3a-mediated metabolism, we used appropriate knockout mouse strains. Results Regorafenib was transported well by mAbcg2 and hABCG2 and modestly by hABCB1 in vitro. Abcg2 and to a lesser extent Abcb1a/1b limited brain and testis accumulation of regorafenib and metabolite M2 (brain only) in mice. Regorafenib oral availability was not increased in Abcg2 -/- ;Abcb1a/1b -/- mice. Up till 2 h, metabolite M5 was undetectable in plasma and organs. Conclusions Brain and testis accumulation of regorafenib and brain accumulation of metabolite M2 are restricted by Abcg2 and Abcb1a/1b. Inhibition of these transporters may be of clinical relevance for patients with brain (micro)metastases positioned behind an intact blood–brain barrier.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, article, cancer, google, scholar, cas, brain, regorafenib, breast, resistance, protein, pglycoprotein, abcg, wagenaar, central, accumulation, schinkel, inhibitor, beijnen, res, sparidans, van, research, oral, plasma, drug, ther, testis, durmus, abcb, barrier, pharmacol, exp, netherlands, human, mice, clinical, bloodbrain, activity, clin, elmquist, distribution, privacy, cookies, content, kort, multikinase, advanced, stromal, efflux,

Topics {✒️}

eu/docs/en_gb/document_library/epar_-_product_information/human/002573/wc500149164 jp/english/service/pdf/drugs/stivarga_mar2010_e month download article/chapter intact blood–brain barrier gov/drugsatfda_docs/nda/2012/203085orig1s000clinpharmr atp-binding cassette transporters b-rafv600e inhibitor vemurafenib van waterschoot ra maximum drug concentration mice lacking mdr1-type molecular cancer therapeutics blood–brain barrier abcg2-mediated active transport metastasized colorectal cancer full article pdf p-glycoprotein-mediated efflux privacy choices/manage cookies advanced solid tumors related subjects lagas js tang sc membrane transporter proteins research paper published netherlands cancer institute axitinib brain accumulation restrict brain accumulation article kort advanced hepatocellular carcinoma european medicines agency major metabolites [abstract] van herwaarden ae drug metab dispos drug/metabolite exposure preliminary antitumor activity oral multikinase inhibitor tumor endothelial signaling 101st annual meeting cytochrome p450 3a cancer gene ther melanoma brain metastases drug export activity oral plasma pharmacokinetics pharmacol exp ther mol cancer ther schinkel receives revenue article log detection p-gp conditions privacy policy alk inhibitor crizotinib mtor inhibitor everolimus

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)
         description:Regorafenib is a novel multikinase inhibitor, currently approved for the treatment of metastasized colorectal cancer and advanced gastrointestinal stromal tumors. We investigated whether regorafenib is a substrate for the multidrug efflux transporters ABCG2 and ABCB1 and whether oral availability, brain and testis accumulation of regorafenib and its active metabolites are influenced by these transporters. We used in vitro transport assays to assess human (h)ABCB1- or hABCG2- or murine (m)Abcg2-mediated active transport at high and low concentrations of regorafenib. To study the single and combined roles of Abcg2 and Abcb1a/1b in oral regorafenib disposition and the impact of Cyp3a-mediated metabolism, we used appropriate knockout mouse strains. Regorafenib was transported well by mAbcg2 and hABCG2 and modestly by hABCB1 in vitro. Abcg2 and to a lesser extent Abcb1a/1b limited brain and testis accumulation of regorafenib and metabolite M2 (brain only) in mice. Regorafenib oral availability was not increased in Abcg2 -/- ;Abcb1a/1b -/- mice. Up till 2 h, metabolite M5 was undetectable in plasma and organs. Brain and testis accumulation of regorafenib and brain accumulation of metabolite M2 are restricted by Abcg2 and Abcb1a/1b. Inhibition of these transporters may be of clinical relevance for patients with brain (micro)metastases positioned behind an intact blood–brain barrier.
         datePublished:2015-01-08T00:00:00Z
         dateModified:2015-01-08T00:00:00Z
         pageStart:2205
         pageEnd:2216
         sameAs:https://doi.org/10.1007/s11095-014-1609-7
         keywords:
            ABCB1
            ABCG2
            brain accumulation
            regorafenib
            testis accumulation
            Pharmacology/Toxicology
            Pharmacy
            Biochemistry
            general
            Medical Law
            Biomedical Engineering and Bioengineering
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig6_HTML.gif
         isPartOf:
            name:Pharmaceutical Research
            issn:
               1573-904X
               0724-8741
            volumeNumber:32
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Anita Kort
               affiliation:
                     name:The Netherlands Cancer Institute
                     address:
                        name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:The Netherlands Cancer Institute/ Slotervaart Hospital
                     address:
                        name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Selvi Durmus
               affiliation:
                     name:The Netherlands Cancer Institute
                     address:
                        name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rolf W. Sparidans
               affiliation:
                     name:Utrecht University
                     address:
                        name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Els Wagenaar
               affiliation:
                     name:The Netherlands Cancer Institute
                     address:
                        name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jos H. Beijnen
               affiliation:
                     name:Utrecht University
                     address:
                        name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:The Netherlands Cancer Institute/ Slotervaart Hospital
                     address:
                        name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:The Netherlands Cancer Institute
                     address:
                        name:Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alfred H. Schinkel
               affiliation:
                     name:The Netherlands Cancer Institute
                     address:
                        name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)
      description:Regorafenib is a novel multikinase inhibitor, currently approved for the treatment of metastasized colorectal cancer and advanced gastrointestinal stromal tumors. We investigated whether regorafenib is a substrate for the multidrug efflux transporters ABCG2 and ABCB1 and whether oral availability, brain and testis accumulation of regorafenib and its active metabolites are influenced by these transporters. We used in vitro transport assays to assess human (h)ABCB1- or hABCG2- or murine (m)Abcg2-mediated active transport at high and low concentrations of regorafenib. To study the single and combined roles of Abcg2 and Abcb1a/1b in oral regorafenib disposition and the impact of Cyp3a-mediated metabolism, we used appropriate knockout mouse strains. Regorafenib was transported well by mAbcg2 and hABCG2 and modestly by hABCB1 in vitro. Abcg2 and to a lesser extent Abcb1a/1b limited brain and testis accumulation of regorafenib and metabolite M2 (brain only) in mice. Regorafenib oral availability was not increased in Abcg2 -/- ;Abcb1a/1b -/- mice. Up till 2 h, metabolite M5 was undetectable in plasma and organs. Brain and testis accumulation of regorafenib and brain accumulation of metabolite M2 are restricted by Abcg2 and Abcb1a/1b. Inhibition of these transporters may be of clinical relevance for patients with brain (micro)metastases positioned behind an intact blood–brain barrier.
      datePublished:2015-01-08T00:00:00Z
      dateModified:2015-01-08T00:00:00Z
      pageStart:2205
      pageEnd:2216
      sameAs:https://doi.org/10.1007/s11095-014-1609-7
      keywords:
         ABCB1
         ABCG2
         brain accumulation
         regorafenib
         testis accumulation
         Pharmacology/Toxicology
         Pharmacy
         Biochemistry
         general
         Medical Law
         Biomedical Engineering and Bioengineering
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-014-1609-7/MediaObjects/11095_2014_1609_Fig6_HTML.gif
      isPartOf:
         name:Pharmaceutical Research
         issn:
            1573-904X
            0724-8741
         volumeNumber:32
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Anita Kort
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:The Netherlands Cancer Institute/ Slotervaart Hospital
                  address:
                     name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Selvi Durmus
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rolf W. Sparidans
            affiliation:
                  name:Utrecht University
                  address:
                     name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Els Wagenaar
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jos H. Beijnen
            affiliation:
                  name:Utrecht University
                  address:
                     name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:The Netherlands Cancer Institute/ Slotervaart Hospital
                  address:
                     name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:The Netherlands Cancer Institute
                  address:
                     name:Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alfred H. Schinkel
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Pharmaceutical Research
      issn:
         1573-904X
         0724-8741
      volumeNumber:32
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute/ Slotervaart Hospital
      address:
         name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
      name:Utrecht University
      address:
         name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
      name:Utrecht University
      address:
         name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute/ Slotervaart Hospital
      address:
         name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Anita Kort
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
            name:The Netherlands Cancer Institute/ Slotervaart Hospital
            address:
               name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Selvi Durmus
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Rolf W. Sparidans
      affiliation:
            name:Utrecht University
            address:
               name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
               type:PostalAddress
            type:Organization
      name:Els Wagenaar
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Jos H. Beijnen
      affiliation:
            name:Utrecht University
            address:
               name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
               type:PostalAddress
            type:Organization
            name:The Netherlands Cancer Institute/ Slotervaart Hospital
            address:
               name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
            name:The Netherlands Cancer Institute
            address:
               name:Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Alfred H. Schinkel
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
      name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
      name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
      name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
      name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
      name:Division of Pharmacoepidemiology & Clinical Pharmacology Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
      name:Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/ Slotervaart Hospital, Amsterdam, The Netherlands
      name:Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
      name:Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(164)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.4s.

LINK . SPRINGER . COM {}